Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Proqr Therapeutics
(NQ:
PRQR
)
1.880
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.880
Bid (Size)
1.800 (526)
Ask (Size)
2.090 (2)
Prev. Close
1.880
Today's Range
1.880 - 1.880
52wk Range
1.110 - 3.290
Shares Outstanding
80,817,079
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 18, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces First Quarter 2024 Operating and Financial Results
May 09, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Performance
YTD
-9.40%
-9.40%
1 Month
+13.94%
+13.94%
3 Month
-6.47%
-6.47%
6 Month
-10.05%
-10.05%
1 Year
+15.34%
+15.34%
More News
Read More
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
May 08, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
4 Analysts Have This to Say About ProQR Therapeutics
August 04, 2023
Via
Benzinga
Analyst Ratings for ProQR Therapeutics
May 17, 2023
Via
Benzinga
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 23, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
April 22, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Year End 2023 Operating and Financial Results
March 13, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
February 15, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
January 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 18, 2024
Via
Benzinga
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
January 05, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Via
Benzinga
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
US Stocks Lower; Dow Falls Over 50 Points
November 27, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
November 08, 2023
Via
Benzinga
ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Second Quarter 2023 Operating and Financial Results
August 03, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
August 01, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.